Feb 04, 2021
Synthetic Bryostatin Available to Expand Neurodegenerative Indication Trials
Dec 02, 2020
Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals
Oct 06, 2020
Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease
Jul 30, 2020
Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of Bryostatin-1, Partially Funded by NIH, for Alzheimer's Disease
May 26, 2020
Neurotrope Announces Investor Update Conference Call
May 18, 2020
Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company
Jan 22, 2020
Neurotrope, Inc. Announces $18 Million Registered Direct Offering
Jan 22, 2020
Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial
Oct 08, 2019
Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value
Sep 09, 2019
Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease
Aug 13, 2019
Neurotrope Announces Publication Highlighting the Potential of Bryostatin as a Unique Neurorestorative Therapy
Aug 05, 2019
Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results
Jul 17, 2019
Neurotrope Strategic Advisory Board Members Participating in Key Opinion Leader Call Sponsored by Oppenheimer's Biotechnology Team
Jul 15, 2019
Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease
Jul 11, 2019
Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented
Jun 03, 2019
Neurotrope's President and Chief Scientific Officer to Present at the Alzheimer's Solutions Conference at The University of the Sciences in Philadelphia, PA on June 3rd, 2019
May 30, 2019
Neurotrope to Present at the LD Micro 9th Annual Invitational Conference on June 4, 2019
Dec 17, 2018
Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease
Sep 26, 2018
Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer's Disease (CTAD2018)
Sep 05, 2018
Neurotrope Enters into Collaboration with the Nemours / Alfred I. duPont Hospital for Children to Initiate a Clinical Trial in Fragile X Syndrome